Drug Topics

CONTINUE TO SITE >

OR WAIT 15 SECS

Cardiovascular Clinical Consult DiabetesGenericsGut HealthHeart HealthImmunizationMigraineOncologyRespiratoryShinglesTechnologyThoughtSpot 2020

AnticoagulantsAutoimmune DiseasesBiosimilarsCBDCOPD ManagementCoronavirusDermatologyDiabetesGenericsGut HealthHeart HealthImmunizationInfluenzaOncologyPain ManagementPediatricsRespiratoryShingles

All NewsAssociation NewsClinical NewsLegal NewsManaged Care NewsNew ProductsTechnologyViewpoints

Expert InterviewsMedical World NewsPodcasts

Chain PharmacyCommunity PracticeHealth Systems

Conference CoverageConference Listing

eNewsletterPrint Subscription

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences and Drug Topics. All rights reserved.

Spotlight

Cardiovascular Clinical Consult
Diabetes
Generics
Gut Health
Heart Health
Immunization
Migraine
Oncology
Respiratory
Shingles
Technology
ThoughtSpot 2020

ClinicalSee All >

Anticoagulants
Autoimmune Diseases
Biosimilars
CBD
COPD Management
Coronavirus
Dermatology
Diabetes
Generics
Gut Health
Heart Health
Immunization
Influenza
Oncology
Pain Management
Pediatrics
Respiratory
Shingles

Advertise
Editorial
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences^™ and Drug Topics. All rights reserved.

FDA may pull digitalis elixirs this month

June 7, 2004

The FDA deadline for digoxin manufacturers to submit an NDA for their products is fast approaching